CJC-IPA Blend 20mg nasal spray by Hudson Science. 333mcg per actuation, dual GH secretagogue combination delivering CJC-1295 and Ipamorelin via intranasal route. Lab tested, discreetly shipped across Canada. Intended for research purposes only.
Format20mg Nasal Spray
Concentration333mcg/Spray
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
The CJC-IPA Nasal Spray combines CJC-1295 and Ipamorelin into a single 20mg metered nasal spray delivering 333mcg per actuation; the same dual GH secretagogue combination as Hudson Science’s lyophilized CJC-IPA Blend vial, in a non invasive intranasal delivery format that eliminates reconstitution and subcutaneous injection requirements entirely. This presentation adds a distinct administration route to CSD’s CJC-1295 and Ipamorelin combination range, making it the only nasal spray format available for this specific peptide pairing.
The intranasal route is pharmacokinetically meaningful for both compounds in this blend. CJC-1295 and Ipamorelin are peptides that face gastrointestinal degradation via oral administration and require parenteral or alternative delivery routes to reach systemic circulation in bioavailable form. Nasal delivery across the olfactory epithelium and nasal mucosa provides direct systemic absorption bypassing gastrointestinal processing, while the proximity to the olfactory nerve pathway additionally supports potential direct CNS access. A relevant consideration given both compounds’ pituitary targets, where hypothalamic proximity through the olfactory route may influence the degree of GHRH and GHS-R1a receptor engagement relative to peripheral subcutaneous injection.
The pharmacological synergy between the two components remains consistent with the injectable blend; CJC-1295’s DAC modified albumin bound GHRH receptor activation sustaining continuous pituitary GHRH receptor stimulation, combined with Ipamorelin’s selective GHS-R1a activation simultaneously suppressing somatostatin tone and directly stimulating somatotroph cells. Ipamorelin’s exceptional GHS-R1a selectivity, producing GH release with documented minimal cortisol, prolactin, and ACTH effects makes it the preferred GHRP partner for CJC-1295 in this blend regardless of delivery route, ensuring the combined GH response is attributable primarily to synergistic GHRH and GHS-R1a pathway co activation without secondary hormonal confounding variables.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity across both peptide components before being made available, with COA documentation available on request. CSD stocks the CJC-IPA combination across both lyophilized injectable vial and this nasal spray format, alongside individual CJC-1295 and Ipamorelin standalone vials, giving researchers complete delivery route and sourcing flexibility from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.
Commonly researched in GH axis stimulation, anti ageing, and body composition research contexts. Browse CSD’s full peptide range for complete sourcing.
